Crescita Therapeutics (TSE:CTX) Sets New 1-Year High – Time to Buy?

Crescita Therapeutics Inc. (TSE:CTX) shares reached a new 52-week high on Tuesday . The company traded as high as C$0.79 and last traded at C$0.79, with a volume of 4646 shares traded. The stock had previously closed at C$0.75.

Crescita Therapeutics Price Performance

The firm has a market capitalization of C$14.71 million, a price-to-earnings ratio of -79.00 and a beta of -1.34. The company’s 50 day moving average is C$0.75 and its 200 day moving average is C$0.58. The company has a quick ratio of 2.29, a current ratio of 2.80 and a debt-to-equity ratio of 17.34.

Crescita Therapeutics (TSE:CTX) last issued its quarterly earnings data on Monday, May 11th. The company reported C($0.06) earnings per share for the quarter. Crescita Therapeutics had a negative return on equity of 2.07% and a negative net margin of 1.38%.The business had revenue of C$5.64 million during the quarter.

Crescita Therapeutics Company Profile

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.